Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Reneo Pharmaceuticals (RPHM)
NASDAQ:RPHM
RESEARCH TOOLSreports
Reneo Pharmaceuticals (RPHM) Stock Price & Analysis
226 Followers
RPHM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.98 - $9.21
Previous Close$1.48
Volume77.00K
Average Volume (3M)276.23K
Market Cap
$49.46M
Enterprise Value-$32.47M
Total Cash (Recent Filing)$82.83M
Total Debt (Recent Filing)$907.00K
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Aug 07, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding33,420,808
10 Day Avg. Volume166,949
30 Day Avg. Volume276,226
Standard Deviation0.31
R-Squared0.00137
Alpha-0.00901
Financial Highlights & Ratios
Price to Book (P/B)0.47
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.49
Forecast
1Y Price Target
$1.25Price Target Upside-15.54% Downside
Rating ConsensusHold
Number of Analyst Covering2
Reneo Pharmaceuticals News
PremiumCompany Announcements
Reneo Pharmaceuticals Announces Merger and Strategic PIPE Investment
Bulls Say, Bears Say
Bulls Say
FinancingReneo has entered into a subscription agreement for a $65M private investment in public equity (PIPE) financing expected to close with the merger.
LeadershipOnKure leadership has a high-quality pedigree in oncology.
MergerMerger with OnKure pivots story towards oncology.
Bears Say
Cost Saving MeasuresThe company implemented cost saving initiatives, including suspension of all mavodelpar development activities and a reduction in force of approximately 90%.
Financial PerformanceRPHM reported a net loss of $8.4M, or ($0.25) per share.
Product DevelopmentThe company suspended mavodelpar development after the pivotal Phase 2b STRIDE study did not meet either primary or secondary efficacy endpoint in primary mitochondrial myopathies.
---
Ownership Overview
58.05% Insiders
12.37% Mutual Funds
3.37% Other Institutional Investors
26.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RPHM FAQ
What was Reneo Pharmaceuticals’s price range in the past 12 months?
Reneo Pharmaceuticals lowest stock price was $0.98 and its highest was $9.21 in the past 12 months.
What is Reneo Pharmaceuticals’s market cap?
Currently, no data Available
When is Reneo Pharmaceuticals’s upcoming earnings report date?
Reneo Pharmaceuticals’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were Reneo Pharmaceuticals’s earnings last quarter?
Reneo Pharmaceuticals released its earnings results on May 07, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.437 by $0.187.
Is Reneo Pharmaceuticals overvalued?
According to Wall Street analysts Reneo Pharmaceuticals’s price is currently Overvalued.
Does Reneo Pharmaceuticals pay dividends?
Reneo Pharmaceuticals does not currently pay dividends.
What is Reneo Pharmaceuticals’s EPS estimate?
Reneo Pharmaceuticals’s EPS estimate is -$0.1.
How many shares outstanding does Reneo Pharmaceuticals have?
Reneo Pharmaceuticals has 33,420,807 shares outstanding.
What happened to Reneo Pharmaceuticals’s price movement after its last earnings report?
Reneo Pharmaceuticals reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.437. Following the earnings report the stock price went up 0.578%.
Which hedge fund is a major shareholder of Reneo Pharmaceuticals?
Among the largest hedge funds holding Reneo Pharmaceuticals’s share is Highbridge Capital Management LLC. It holds Reneo Pharmaceuticals’s shares valued at 5M.
---
Reneo Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.25 (-15.54% Downside)
$1.25 (-15.54% Downside)
Blogger Sentiment
Bullish
RPHM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $639.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.35%
12-Months-Change
Fundamentals
Return on Equity
-84.01%
Trailing 12-Months
Asset Growth
-14.39%
Trailing 12-Months
Company Description
Reneo Pharmaceuticals
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
---
RPHM Stock 12 Month Forecast
Average Price Target
$1.25
▼(-15.54% Downside)
Technical Analysis
Merck & Company
―
Rocket Pharmaceuticals
―
Adverum Biotechnologies
―
BioMarin Pharmaceutical
―
Best Analysts Covering RPHM
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-40.55%
reiterated a sell rating 4 months ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -40.55% per trade.
---